Any one hear remember IDB? IDB Biomedical had pioneered a nasally administered flu vaccine. The company made a meteoric rise from 4 to 40 then pulled back to ten dollars and then made a move back to 30 very quickly. It was eventually purchased by GSK , Glaxo Smith Kline in 2005 for 35 dollars a share. At the time the SARS epidemic was weighing heavy on people and threats of global pandemics etc.
This is interesting back ground because I think the potential for RVX in capturing a portion of CVD market is at least worth 1 B conservatively and as much as 5 on the long end. IDB was purchased for 1.7 BILLION by GSK. In my view if RVX drug is successful it should be at least worth the same as IDB product was.
At 1 B take over its 14 a share and at 1.7 its worth about 22 a share. Kudos to management for not diluting the pi@@ out of the shares. This is a very small float for a company rich in prospects . The interesting thing is when you go to the RVX website and look under ANALYST COVERAGE there is only one SINGLE ANALYST following the stock. Thats not under the radar folks its not even ABOVE THE GROUND.
This is a mystery of incredible magnitude. Is this because people were burned at 30 dollars in the dotcom phase never to revisit it? Or is it because of the last two spikes which never lasted very long before the stock crashing prior to its recent ascent. Then we have the mysterious Ken Dart. I invite all of you to google this guy on www.kendart.com. This guy owns alot of shares and could be another potential billionaire just with this holding alone.
The other interesting thing is ASSURE trial was conducted almost immediately after SUSTAIN trial concluded. All drug development companies watch their dollars carefully. A lott of companies mismanaged a cycle and now are at ten year lows with no cash in the kitty. sometimes a PP at a high is a GOOD THING. If you dont beleive me look at how much diluution would be necessary for cash strapped Theratechnologies or Bioniche TH and BNC respectively.
I like that one trial went on immediately after the next. Companies dont throw away monies recklessly. Had there been any issues which needed further study, ( lets call it tweeking ) they would have gone back to drawing board for further study. Not so so the results must have exceeded even their best targets. If Phase 2 validates that trend we cal almost surmise that Phase 3 ,even on reduced efficacy, could yeild a winner. On the macro front global pharma stocks are at highest level in years, and with an aging population, and ever increasing pollution, the macro economic chips are all in RVX favour.
Ken Dart the mysterious man in the Caymans has alot of investments proposals that come his way, yet he SOUGHT out RVX.
Very Interesting .......